Figure 2.
Survival outcomes of epcoritamab vs SOC/CIT. (A) PFS; (B) OS. Comparisons of survival outcomes for epcoritamab vs SOC/CIT were adjusted to account for any reported impact of COVID-19.
Survival outcomes of epcoritamab vs SOC/CIT. (A) PFS; (B) OS. Comparisons of survival outcomes for epcoritamab vs SOC/CIT were adjusted to account for any reported impact of COVID-19.
